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ALLOGRAFT HEART VALVE 
STERILIZATION: A SIX-YEAR 
IN-DEPTH ANALYSIS OF 
A TWENTY-FIVE-YEAR 
EXPERIENCE WITH LOW- 
DOSE ANTIBIOTICS 
At the Prinee Charles Hospital, from a 25-year experience with allograft 
heart valves (1969 to 1994), a 6-year analysis from March 1988 to August 
1994 of the contamination rates and efficiency of a short-duration, low-dose 
antibiotic sterilization protocol was made. This analysis covered 642 
collections and 680 aortic and pulmonary valve implants. Tissue samples 
obtained at collection, valve trimming, postantibiotic incubation, and 
implant provided the raw data. At collection, valves retrieved in open 
mortuaries produced the highest contamination rate of 54%. Minimal 
exposure to antibiotics during transport and trimming reduced the con- 
tamination rate to 11% (p < 0.05). This was similar to the contamination 
rate at trimming for valves collected in the "sterile" operating room from 
multiorgan donors (12%). Antibiotic incubation at 37°C for 6 hours 
reduced the contamination rate to 4% (p < 0.05). Only valves that 
showed no contamination at cryopreservation were implanted. However, 
at implant, resected tissue from valves that had been incubated in 
antibiotics showed a contamination rate of 3%, presumably from the 
theater environment, compared with 15% (p < 0.05) for tissue from 
valves that had not been incubated. A residual antibiotic eIfect appears 
present at the time of implant in valves that have been incubated in 
antibiotics and may assist in the reduction of and resistance to infection 
in the immediate postoperative period. This is supported by the low 
incidence of endocarditis in the first 3 postoperative months. The simple 
and effective protocol of collection within 24 hours of death combined 
with low-dose antibiotic sterilization is sutficient o produce pathogen- 
free valves in the majority of cases (>95%). (J TtIORAC CARDIOVASC 
SURG 1995;110:680-7) 
Ken Gall, BAS, Susan Smith, BSc, Christene Willmette, EN, 
Mae Wong, FRCPA, and Mark O'Brien, FRACS, FRCS, Brisbane, Australia 
T he clinical use of allograft valves for aortic valve replacement has been markedly limited by their 
availability. Whereas in  many centers allograft 
valves have been obtained primarily from multior- 
gan donors, supply has been increased by postmor- 
tern retrieval and retrieval from the excised heart of 
the transplant recipient. Even so, all three sources 
may be insufficient o meet clinicat requirements. 
In the past postmortem retrieval necessitated the 
From the Department of Cardiac Surgery, The Prince Charles 
Hospital, Chermside, Brisbane, Australia. 
Received for publication August 11, 1994. 
Accepted for publication Jan. 11, 1995. 
Address for reprints: Mark F. O'Brien, FRACS, FRCS, Depart- 
ment of Cardiac Surgery, The Prince Charles Hospital, Rode 
Rd., Chermside, Brisbane 4032, Australia. 
Copyright © 1995 by Mosby-Year Book, Inc. 
0022-5223/95 $ .00 + 0 12/1/63201 
680 
use of chemical, irradiation, or other harsh methods 
of valve sterilization that, coupled with the methods 
of storage, 1'2 led to poor clinical durability. 3' 4 As a 
result, interest in the use of the allograft waned 
during the 1965 to 1980 era. The inherent problem 
of microbial contamination from the mortuary at- 
mosphere and the respiratory and gastrointestinal 
systems after death had to be overcome without 
damaging the valve. » Gentle antibiotic sterilization 
produced a valve that could be stored at 4 ° C 6 and, 
since the mid-1970s, cryopreserved in liquid nitro- 
gen. 7 
Allograft valves were first used at The Prince 
Charles Hospital (TPCH) in 1969 and the clinical 
results of allografts stored at 4°C and after early 
cryopreservation have been documented. TM Inter- 
est in the maintenance of valve leaßet viability, ~2 
considered a probable important determinant of 
long-term function, 13-14 led to a review of the anti- 
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Table I. Evolution of TPCH allografl valve antibiotic sterilization and storage protocol 
37 ° C incubation Storage time 
Era Antibiotics time (hr) Storage type maximum 
1969-75 P, S, A 24 Refrigerated 4 ° C 72 days 
1975-88 P, S, A 24 Cryopreserved Indefinite 
1988- P, S 6 Cryopreserved Indefinite 
P, Penicillin (30 ~g/ml); S, streptornycin (50/.~g/ml); A, arnphotericin B (10/xg/ml). 
biotic sterilization protocol at TPCH in March 1988. 
Formerly, from 1969 to 1988, low-dose penicillin, 
streptomycin, and amphotericin B were the antibi- 
otics used to sterilize valve tissue by incubation in 
nutrient medium for 24 hours at 37 ° C. The antifun- 
gal agent, amphotericin B, was removed from the 
antibiotic mixture because of its deleterious effects 
on cell viability during the cryopreservation process, 
which left a low-dose antibiotic mixture of penicillin 
and streptomycin. Incubation time was reduced 
when a series of bacteriologic tests at TPCH indi- 
cated that a 6-hour incubation in antibiotics was just 
as effective as a 24-hour incubation i  reducing 
microbial contamination. The tissue from beating- 
heart donors received a minimal antibiotic exposure 
of 30 to 60 minutes at room temperature during 
processing of the valve, whereas tissue obtained 
from postmortem donors received a 6-hour 37°C 
incubation before cryopreservation. Because antibi- 
otics act against organisms during their replication, 
it is maintained that maximum antibiotic action is 
achieved by incubation of tissue at 37 ° C. In addi- 
tion, cellular viability may be improved at 37°C 
rather than at 4 ° C. Antibiotic sterilization at 4°C 
has never been used at TPCH. Even during the 
period 1969 to 1975, before cryopreservation, valves 
were always incubated in antibiotics at 37 ° C before 
4 ° C storage in nutrient medium without antibiotics. 
In April !991, results of a review of contamination 
rates in multiorgan donor valves retrieved in an 
operating room led to these valves also being incu- 
bated for  6 hours at 37 ° C. 
Thus the current sterilization protocol is low- 
dose and short exposure to minimize any harmful 
effects on valve viability. This objective was 
achieved w~th strict sterility testing during all 
phases of processing with the eventual production 
of a pathogen-free valve for implantation. The 
evolution of the antibiotic sterilization and stor- 
age protocols for allograft valves at TPCH since 
1969 is expressed in Table I. 
Various alternative antibiotic sterilization proto- 
cols have been developed by others with different 
Table II. Collection types and postcollection treatment 
Type and treatment No. 
Donor 
With 37 ° C incubation in antibiotics (6 hr) 
Multiorgan donor 53 
No incubation 
Multiorgan donor 71 
Heart transplant recipient 47 
Total donor 171 
Postmortem 
Collection solution with antibiotics 345 
No collection solution 126 
Total postmortem 471 
Total collections 642 
antibiotics, concentrations, exposure times, and in- 
15 17 cubation temperatures. - This paper examines the 
allograft valve contamination rates and the etti- 
ciency of sterilization by the short, low-dose proto- 
col currently in use at TPCH. The analysis covers 
the experiences of a surgical unit that now implants 
some 150 allograft valves each year in cases of 
acquired and congenital heart disease. 
Material and methods 
Valve collection type. During the period of review, 
from March 1988 to August 1994, 642 collections were 
made from two distinct sources termed donor and 
postmortem. Beating-heart multiorgan donors and 
hearts from heart transplant recipients, both retrieved 
in operating rooms, provided 171 donor valve collec- 
tions. Procurement immediately before postmortem 
examination provided 471 postmortem collections. 
Among these retrievals, 345 were from the large open 
mortuary room and 126 were done in a "clean room" 
environment apart from the main mortuary room. For 
postmortem retrievals the skin was carefully sterilized 
and the body draped as for a surgical operation and the 
excision was regarded as a "clean" nonsterile proce- 
dure. Procurement of heart valves from postmortem 
sources has always been rigidly maintained within 24 
hours of death (mean death to collection time: 15 
hours). The antibiotic procedure and the effectiveness 
of sterilization of valves from the two sources, donor 
and postmortem, were collated into subgroups accord- 
ing to the step-by-step procedures after collection. The 
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numbers and subgroups of the collection types are 
shown in Table II. 
Microbiology specimens. Fungal and bacterial contam- 
ination of the allograft valves was monitored by strict 
sterility testing of specimens during the collection and 
processing steps. Specimens were obtained as follows. 
Collection. The amount of tissue obtained and the 
shipping method were dependent on the collection type 
and source. For donor collection, the entire heart was 
shipped, double wrapped, in sterile plastic bags on wet ice. 
Samples for sterility testing were not obtained at retrieval 
from such donor collections. The majority of postmortem 
valves were obtained as a heart-valve block consisting of 
the aortic and pulmonary valves, anterior leaflet of the 
mitral valve, subvalvular myocardium, and associated 
great vessels. The heart-valve blocks were placed in the 
collection solution, which consisted of nutrient medium 
199 (M199; CSL, Parkville, Victoria, Australia) containing 
the antibiotics (M199+Aß) penicillin (CSL) (30 p~g/ml) 
and streptomycin (CSL) (50 tzg/ml). Valves were trans- 
ported on cold packs to TPCH allograft heart valve unit. 
Postmortem collections into M199+Aß provided a tissue 
sample at collection, apericardial swab, and the collection 
solution for sterility testing. Postmortem valve collections 
from clean rooms resulted in heart-valve blocks and entire 
hearts being shipped without M199+Aß in double- 
wrapped sterile plastic bags on wet ice. Postmortem 
retrievals without M199+Aß provided a pericardial swab 
only for sterility testing at the time of collection. 
Trimming. All valves were processed within 6 hours of 
receipt. The vast majority were trimmed immediately. 
Early in the TPCH experience, trimming of the valves was 
done in an operating theater. In more recent years, a 
lamina flow cabinet in a clean room dedicated to heart 
valve processing has been used. All valves were regularly 
moistened with M199+Aß to ensure leaflets did not 
dehydrate during the trimming process. After trimming, 
all valves were rinsed in M199 without antibiotics to wash 
oft any blood and adhering tissue pieces. The rinse 
solution did not contain antibiotics and was used to 
promote the growth of any contaminating organisms that 
may have been on the surface of the tissue. Sampies of 
tissue trimmings and the rinse solution were used for 
sterility testing. 
Incubation. All postmortem valves were incubated in 
M199+AB for 6 hours at 37 ° C before cryopreservation. 
Donor valves from multiorgan donors since April 1991 
were similarly incubated, whereas those from heart trans- 
plant recipients were not incubated. A piece of tissue was 
included with each incubated valve for sterility testing 
after valve incubation. 
Cryopreservation. Valves were cryopreserved in 100 ml 
M199 (without antibiotics) with 10% dimethyl sulfoxide 
(DMSO) (Merck, Darmstadt, Germany) at a rate of 
approximately -1°C  per minute in a controlled rate 
freezer (model 1010A, Cryomed, Mt. Clemens, Mich.) to 
a temperature of -40°C and then transferred to the 
vapor phase of a liquid nitrogen freezer (17K, Taylor- 
Wharton, Indianapolis, Ind.) at temperatures lower than 
-135 ° C. A piece of incubated tissue, the incubation 
solution, and a sample of the freezing solution were used 
for sterility testing. 
Thawing and clinical implantation. For implantation the 
valves were thawed in a 37 ° C saline bath followed by a 4 
by 2-minute sequential dilution washout of the cryopro- 
tectant (5% DMSO, 2.5% DMSO, M199 only, M199 
only). Tissue segments from the trimming of the valve 
before insertion at the surgical operating table and the 
freezing solution were used for sterility testing. Only those 
valves implanted at TPCH are included in this analysis. 
Microbiologic methods. Pericardial swabs were used to 
inoculate horse blood agar (Oxoid, Unipath Limited, 
Basingstoke, Hampshire, England) plates and Sabouraud 
dextrose agar (Unipath) slopes (SAß). All tissue samples 
were roughly chopped and placed into nutrient broth 
(Unipath) and thioglycolate broth (Unipath) and incu- 
bated at 35 ° C for 48 hours. The broths were then plated 
onto horse blood agar plates. The subculture from the 
nutrient broth was incubated aerobically for a further 48 
hours at 35 ° C. The thioglycollate broth subculture was 
incubated anaerobically for a further 48 hours at 35 ° C. 
Collection, rinse, and freezing solutions were incubated 
for 48 hours at 35 ° C followed by subculturing onto horse 
blood agar plates, which were incubated for a further 48 
hours at 35 ° C. Rinse solutions and freezing solutions at 
cryopreservation were inoculated onto SAß slopes. SAß 
slopes were incubated at 30°C for 21 days before they 
were read. All subculturing of samples and organism 
identification was done by the microbiology laboratory of 
the pathology department of TPCH. Valves were not 
made available for clinical use until all samples taken 
immediately before cryopreservation were shown to be 
free of any bacterial or fungal contamination. 
For each valve processed for clinical implantation, there 
were up to 12 specimens (6 solutions, 5 tissue pieces, and 
a pericardial swab) tested for sterility. A summary of the 
samples used for sterility testing is contained in Table III. 
Because tissue pieces were the only samples tested for 
sterility at every stage of valve processing, cryopreserva- 
tion, and implantation, results of contamination rates for 
tissue samples form the basis of this review. 
Statistical analysis. Data were entered into a spread- 
sheet program (Exel, Microsoft Corporation, Redmond, 
Wash.) and X z tests were done to determine possible 
differences in contamination levels between comparable 
tissue groups. Ap value <0.05 was considered statistically 
significant. 
Results 
Results for each valve type and subgroup are 
expressed in Tables IV to VII I .  Tables IV and V 
show microbial contamination rates for multiorgan 
donor valves with and without antibiotic incubation, 
respectively. Table VI  shows contamination in the 
heart transplant re¢ipient donor group. Tables VI I  
and V I I I  indicate contamination for postmortem 
valves collected with and without antibiotic collec- 
tion solution, respectively. Table IX is a compilation 
of the results for all valves separated into those 
incubated in antibiotics and those not incubated. 
The discard rate as a result of microbiologic on- 
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Table III. Samples for sterility assessment obtained at valve collection, trimming, cryopreservation, and 
implantation for valves collected from donor and postmortem groups 
Donor Postmortem 
With No Collection No collection 
Sample incubation incubation solution solution 
At collection 
Pericardial swab - -  - -  Yes Yes 
Tissue - -  - -  Yes - -  
Collection solution - -  - -  Yes - -  
At valve trimming 
Tissue Yes Yes Yes Yes 
Rinse solution Yes Yes Yes Yes 
At cryopreservation 
Postlncubation aortic tissue Yes - -  Yes Yes 
Incubation solution aortic Yes - -  Yes Yes 
Postincubation pulmonary tissue Yes - -  Yes Yes 
Incubation solution pulmonary Yes - -  Yes Yes 
Freezing solution Yes Yes Yes Yes 
At implantation 
Tissue Yes Yes Yes Yes 
Freezing solution Yes Yes Yes Yes 
Table IV. Contamination rates and commonly isolated organisms in tissue samples obtained from multiorgan 
donor valves incubated for 6 hours at 37 ° C in M199+AB 
Tissue sample Samples contaminated Common isolates 
Source n n % CI Organism n 
Trimming 53 5 9 3-21 Staphylococcus epidermidis 2 
Candida albicans 1 
Coliforms 1 
S. aureus 1 
Acinetobacter sp. 1 
Aortic postincubation 53 1 2 0-11 Candida albicans 1 
Pulmonary postincubation 53 1 2 0-11 Candida albicans 1 
Aortic at in'lplant 32 1 3 0-16 S. epidermidis 1 
Pulmonary at implant 29 0 0 0-12 - -  
Total a t  implant 61 1 2 0-10 S. epidermidis 1 
C/, 95% confidence interval. 
tamination was low. Of the 642 collections 31 (5%) 
showed contamination bybacteria or fungi in tissue 
or solution samples at the time of cryopreservation 
and the valves from these collections were dis- 
carded. In the immediate postoperative p riod (<30 
days) endocarditis developed inonly two patients. In 
both cases the causative organism was not present in 
any samples during valve processing. The actuarial 
freedom from endocarditis at15 years in the current 
group of patients who received cryopreserved valves 
is 94% +_ 2%. 
Discussion 
The high contamination rate of multiorgan donor 
valves at trimming, 9% to 14% (Tables IV and V), is 
similar to that in published ata. 5' 6, 16 At trimming 
donor valves showed the presence of skin, respira- 
tory, and gastrointestinal tract flora. The gastroin- 
testinal tract organisms, Candida albicans and coli- 
forms, indicated possible contamination during 
retrieval. This could occur if the bowel was perfo- 
rated during the removal of mesenteric lymph nodes 
for tissue typing purposes and the heart was subse- 
quently removed with the same instruments. 
The heart ransplant recipient valve group was the 
only donor group with a low contamination rate 
(2%) at trimming (Table VI). This group differs 
from multiorgan donors in two important areas. 
First, all hearts were excised by TPCH cardiac 
surgeons with a very short time exposure to the 
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Table V. Contamination rates and commonly isolated organisms in tissue samples obtained from multiorgan 
donor valves not incubated in M199+AB 
Tissue sample Samples contaminated Common isolates 
Source n n % CI Organism n 
Trimming 71 10 
Aortic at implant 56 13 
Pulmonary at implant 43 8 
Total at implant 99 21 
14 7-24 Staphylococcus epidermidis 3 
S. aureus 2 
Coliforms 2 
Viridans streptococcus 2 
23 13-36 S. epidermidis 7 
Diphtheroid sp. 2 
19 9-34 S. epidermidis 4 
Diphtheroid sp. 2 
21 13-30 S. epidermidis 11 
Diphtheroid sp. 4 
CI, 95% confidence interval. 
Table VI. Contamination rates and cornmonly isolated organisms in tissue samples obtained from heart 
transplant recipient valves not incubated in M199+AB 
Tissue sample Samples contaminated Common isolates 
Source n n % CI Organism 
Trimming 47 1 2 0-12 Staphylococcus aureus 
Aortic at implant 38 0 0 0-10 - -  
Pulmonary at implant 1 0 0 - -  - -  
1 
C1, 95% confidence interval. 
Table VII. Contamination rates and commonly isolated organisms in tissue samples obtained from 
postmortem valves collected into M199+AB 
Tissue sample Samples contaminated Common isolates 
Source n n % CI Organism n 
Collection 339 184 54 48-60 
Trimming 345 38 11 8-15 
Aortic postincubation 345 13 4 2-7 
Pulmonary postincubation 342 11 3 1-5 
Aortic at implant 244 3 1 0-3 
Pulmonary at implant 101 6 6 2-13 
Total at implant 345 9 3 1-5 
Staphylococcus epidermidis 70 
Viridans streptococcus 58 
Nonhemolytic streptococcus 28 
Coliforms 17 
Group B/3-hemolytic streptococcus 16 
S. aureus 15 
Bacillus sp. 11 
Viridans streptococcus 9 
Coliforms 10 
S. epidermidis 5 
Pseudomonas sp. 4 
Coliforms 7 
Coliforms 4 
Pseudomonas sp. 2 
S. epidermidis 3 
S. epidermidis 2 
S. epidermidis 5 
C/, 95% confidence interval. 
theater environment and, second, the thoracic cavity 
was completely isolated from the abdominal cavity. 
Postmortem valves retrieved in open mortuary 
areas show a very high rate of mierobial contamina- 
tion at eollection (54%) (Table VII). The most 
common isolates were skin and respiratory flora, 
which indicated contamination from the mortuary 
atmosphere during eollection. This is to be expected 
inasmuch as tissue may be exposed to atmospheric 
fallout for up to 10 minutes during collection. This 
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Table VIII. Contamination rates and commonly isolated organisms in tissue samples obtained from 
postmortem valves not collected into M199+AB 
Tissue sample Samples contaminated Common isolates 
Source n n % CI Organism n 
Trimming 126 13 
Aortic postincubation 126 6 
Pulmonary postincubation 125 2 
Aortic at implant 91 4 
Pulmonary at implant 45 4 
Total at implant 136 8 
10 5-17 Viridans streptococcus 3 
Coliforms 3 
Gram-negative bacillus 2 
Staphylococcus aureus 2 
5 2 -11  Gram-negative bacillus 2 
Candida albicans 1 
Coliforms 1 
2 1-7 Gram-negative bacillus 1 
S. aureus 1 
4 1-10 S. epidermidis 2 
9 2-22 S. epidermidis 2 
6 2-12 S. epidermidis 4 
CI, 95% confidence interval. 
Table IX. Contamination rates for tissue samples obtained from all valves that were incubated in M199+AB 
and those not incubated in M199+AB 
Incubated Not incubated 
Contamination Contamination 
Tissue source SampIes (n) n % CI Samples (n) n % CI 
Collection 339 184 54 48-60 . . . .  
Trimming 524 55 11 8-14 118 11 9 4-16 
Aortic postincubation 524 20 4 2-6 . . . .  
Pulmonary postincubation 520 14 3 1-5 . . . .  
Aortic at implant 367 8 2 1-4 94 13 14 7-23 
Pulmonary at implant 175 10 6 2-11 44 8 18 7-31 
Total implant 542 18 3 1-5 138 21 15 10-23 
CI, 95% confidence interval. 
high level of contamination is significantly reduced 
to 11% (p < 0.05) by the time the valve is trimmed. 
This indicates the effectiveness of a short exposure 
to an antibiotic solution during transportation from 
the collection site to the processing site and during 
valve trimming. In addition, being atmospheric, the 
majority of contamination is washed from the sur- 
face of the heart-valve block during transport in 
nutrient medium with antibiotics. 
Samples taken at trimming of postmortem valves 
with no collection solution (Table VII) demon- 
strated a level of contamination (10%) similar to 
that of postmortem valves with collection solution 
(11%) at the time of trimming. This is probably in 
part the result of the retrieval of these valves from 
clean room environments. This low rate of contam- 
ination was also similar to that of donor valves at 
trimming (9% to 14%) (Tables IV and V). 
A 37 ° C, 6-hour incubation in M199+AB signifi- 
cantly reduced contamination from 11% to 3% or 
4% (p < 0.05) (Table IX). This indicated that the 
type of antibiotics, the low concentrations of the 
antibiotics, the incubation temperature, and the incu- 
bation period are sufficient to sterilize the vast 
majority of heart valves processed. 
Because only those valves that had no demonstra- 
ble contamination in tissues or solutions at the time 
of cryopreservation were implanted, it can be in- 
ferred that any contamination at the time of implant 
arose from the operative field. Furthermore, tissue 
samples at implant showed contamination bycom- 
mon skin flora, such as Staphylococcus epidermidis, 
Micrococcus p., and diphtheroids, which also sug- 
gests contamination from the operative field. As 
seen from Table IX, at implant, valves that were not 
incubated in M199+AB showed a much higher ate 
of contamination (15%) compared with the rate in 
valves that had been incubated (3%) (p < 0.05). The 
valves that were incubated with antibiotics appeared 
to have a residual antibiotic effect that destroyed 
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contaminating bacteria or inhibited their growth. 
The presence of antibiotics in the implanted tissue 
may play a contributory role in the early postoper- 
ative period during which allografts demonstrate a 
low rate of bacterial endocarditis s compared with 
other valve prostheses. During the whole experience 
at TPCH only two patients who received allograft 
valves had endocarditis after operation in the first 3 
months. In both cases the causative organism was 
never present in any of the many samples tested for 
sterility during valve processing. In the presenee of 
active endocarditis, no implanted allograft valve was 
affected by endocarditis,  
Amphotericin B has been removed from some 
valve incubation protocols 1°' 16 because of its effect 
on viability. Fungal contamination of valves in this 
review was low (<2%) and often associated with 
contamination by other gastrointestinal tract organ- 
isms such as coliforms. The presence of gastrointes- 
tinal tract organisms in postmortem valves is likely a 
result of microbial migration through the blood 
stream and diaphragm in the postmortem interval. 
With maintenance of a strict protocol of retrieval 
within 24 hours of death (mean 15 hours) such 
contamination was minimized. Valves showing con- 
tamination with fungal organisms at cryopreserva- 
tion were discarded. This protocol of early retrieval 
has been in effect for 25 years since the commence- 
ment of the allograft heart valve program at TPCH. 
The aspect of clean removal as soon as possible after 
death is considered most important. Donor valves 
with contaminating gastrointestinal tract flora were 
probably procured after all other organs and lymph 
nodes had been removed or possibly when isolation 
between the thoracic and abdominal operative fields 
had not been maintained. Improvements in tech- 
nique have minimized these risks. 
The postmortem retrieval of valves from cadav- 
ers can produce valves with microbial contamina- 
tion levels as low as those obtained from multior- 
gart donors in a sterile theater environment by the 
time of the trimming step of processing. Short- 
term exposure to antibiotics during transportation 
or trimming may wash oft surface contaminants 
from atmospheric fallout during retrieval. Incuba- 
tion of valve tissue in penicillin, 30 ~g/ml, and 
streptomycin, 50 ~g/ml, at 37 ° C for 6 hours is a 
sufficient antibiotic treatment o decontaminate 
the vast majority of valves and has the benefits of 
being low cost, nontoxic, and convenient. Procure- 
ment of valves within 24 hours of death at post- 
mortem examination produces valves with low 
levels of contamination by gastrointestinal tract 
organisms. 
The TPCH protocol for allograft heart valve 
antibiotic sterilization is unlikely to be effective if 
collection from postmortem sources is prolonged 
beyond 24 hours of death, if there is any delay in 
transport before the valves are processed, and in 
particular if antibiotics are not used immediately at 
postmortem collection. It is recognized that the 
penicillin and streptomycin regimen is different 
from the modern-day broad-spectrum ultiple an- 
tibiotic regimen used by most centers and tissue 
banks. At TPCH, this protocol has stood the test of 
time (25 years), has proved effective, and demands 
no change. 
Recommendations 
1. Retrieve valve as soon as possible after death. 
2. Retrieve valve in as sterile a manner as possible. 
3. Expose all valves to antibiotics. For heart-only 
donor and transplant recipient valves, minimal 
exposure during trimming of the valves is suffi- 
cient. All other valves should be considered 
contaminated and be incubated in nutrient me- 
dium with antibiotics for 6 hours at 37 ° C. 
4. If there is any doubt about he sterility, the protocol 
is (1) thaw and culture the pulmonary valve, (2) 
perform a Gram stain procedure on the freezing 
solution while the DMSO is being washed from the 
valve just before implant, or (3) discard. 
5. Discard all valves that demonstrate fungal con- 
tamination at trimming. 
6. Specimens of tissue trimmed from grafts at the 
time of implant taust be sent for culture. It is 
important clinically to know the valve is sterile to 
correlate this with the subsequent progress of the 
patient's condition. 
7. Procurement personnel should remove the heart 
from multiorgan donors with new gloves and 
clean instruments, and if possible the thoracic 
and abdominal operative fields should be isolated 
to reduce the risk of contamination from the 
gastrointestinal system. 
8. Any surgical department intending to adopt this 
TPCH protocol of low-dose, short-exposure an- 
tibiotic sterilization must ensure collection is 
done within 24 hours of death and ascertain its 
own initial and follow-up contamination rates. 
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